Loading clinical trials...

Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET | Clinical Trials | Clareo Health

UNKNOWN

Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET

Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of Poor Ovarian Response (POR) Clinical Outcome in Patients Undergoing in Vitro Fertilization / Embryo Transfer (IVF/ET)

NCT02801591•Changchun GeneScience Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection assisted in the treatment of the patients with poor ovarian response in vitro fertilization and embryo transfer.

Eligibility

Age

30 - 42 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Female, age 30-42 years old.
•Diagnosis of POR (2011 ESHRE Bologna Standard).
•At least two previous IVF failure history.
•Voluntarily to sign the "informed consent".

Exclusion Criteria

•Severe acute and chronic liver and kidney disease，Such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity period, etc.；Liver and kidney dysfunction.
•Endocrine and metabolic diseases，eg, diabetes、Thyroid function hyperthyroidism, Thyroid dysfunction, cushing's syndrome, hyperprolactinemia，hyperandrogenism.
•Related diseases affecting outcome of IVF pregnancy，eg, hydrosalpinx, hysteromyoma≥4cm, adenomyosis, stage III and IV endometriosis, untreated endometrial lesions, uterine malformation, genital tuberculosis, malignant tumor of reproductive system （include endometrial carcinoma, cervical carcinoma, ovarian cancer, fallopian tube carcinoma）.
•Allergic to E. coli expression product and its excipients.
•Subjects who participated in the past three months or are participating in other drug clinical researchers.
•IVF failure history≥3.
•The researchers consider who is not suitable for enrolling the group.

Locations (2)

Peking University Third Hospital

Beijing, China

People's Hospital of Peking University

Beijing, China

Key Dates

Start Date

February 1, 2016

Primary Completion Date

February 1, 2017

Last Updated

June 16, 2016

Enrollment

240

ESTIMATED participants

Conditions

Poor Ovarian Response

Interventions

Conventional ovarian stimulation proctol without rhGH

PROCEDURE

Contacts

Rui Yang

CONTACT

010-82265080

Proteomic and Biological Characterisation of Plasma for the Study of Changes Following Ovarian Reactivation Treatment

NCT07376460

Poor Ovarian ResponseOvarian Reactivation

View study

TERMINATEDPHASE3

Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial

NCT02418572

InfertilityPoor Ovarian Response

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 16, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET

Inclusion Criteria

Exclusion Criteria

Proteomic and Biological Characterisation of Plasma for the Study of Changes Following Ovarian Reactivation Treatment

Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial

A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve

Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure

Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response

Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders